ComplicationsBy Mayo Clinic staff
Asthma of any kind — including exercise-induced asthma — may cause a number of complications. Proper treatment can help you avoid them. Possible asthma complications include:
- Poor athletic performance
- Permanent narrowing of the airways (bronchial tubes), which causes difficulty breathing
- Emergency room visits and hospitalizations for severe asthma attacks
- Krafczyk MA, et al. Exercise-induced bronchospasm: Diagnosis and management. American Family Physician. 2011;84:427.
- Pathogenesis, prevalence, diagnosis, and management of exercise-induced bronchoconstriction: A practice parameter. Palatine, Ill.: The American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. http://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/Exercise-induced-bronchoconstriction-2011.pdf. Accessed Sept. 26, 2011.
- Rakel D. Pulmonary problems. In: Rakel D. Integrative Medicine. 2nd ed. Philadelphia, Pa.: Saunders Elsevier; 2007. http://www.mdconsult.com/das/book/body/208746819-2/0/1494/0.html. Accessed Sept. 26, 2011.
- Asthma and exercise: Tips to remember. American Academy of Allergy, Asthma and Immunology. http://www.aaaai.org/conditions-and-treatments/library/asthma-library/asthma-and-exercise.aspx. Accessed Sept. 26, 2011.
- Exercise-induced asthma. Asthma and Allergy Foundation of America. http://www.aafa.org/display.cfm?id=8&sub=17&cont=168. Accessed Sept. 26, 2011.
- Parker MJ. Asthma. Otolaryngology Clinics of North America. 2011;44:667.
- Covar RA, et al. Allergic disorders. In: Hay WW, et al. Current Diagnosis & Treatment: Pediatrics. 20th ed. New York, N.Y.: The McGraw-Hill Companies; 2011. http://www.accessmedicine.com/content.aspx?aID=6589316. Accessed September 26, 2011.
- Expert panel report 3 (EPR-3): Guidelines for the diagnosis and management of asthma. Bethesda, Md.: National Institutes of Health. http://www.nhlbi.nih.gov/guidelines/asthma/07_sec3_comp4.pdf. Accessed Sept. 26, 2011.
- Updated information on leukotriene inhibitors: Montelukast (marketed as Singulair), zafirlukast (marketed as Accolate), and zileuton (marketed as Zyflo and Zyflo CR). U.S. Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm165489.htm. Accessed Sept. 26, 2011.
- FDA drug safety communication: New safety requirements for long-acting inhaled asthma medications called long-acting beta-agonists (LABAs). U.S. Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200776.htm. Accessed Sept. 26, 2011.
- Asthma action plan. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/public/lung/asthma/asthma_actplan.pdf. Accessed Sept. 27, 2011.